NIH R01 · 2025
Towards a more generalizable genomic risk classification for acute myeloid leukemia (AML)
Acute myeloid leukemia (AML) is the most common adult acute leukemia. Molecular features such as cytogenetics and somatic mutations are essential components of risk stratification; used in daily clinical practice to determine treatment modality and intensity. Our knowledge of recurrent genetic AML-associated features, survival associations, subsequent genetic risk classification and clinical practice is informed by large-scale genomic studies performed over the past decade. Current clinical practice is predicated on the supposition that adequate testing has been performed and that genetic background should not interplay with the known AML-associated genetic and genomic landscape or with…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.